Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;51(12):3239-3242.
doi: 10.1002/eji.202149296. Epub 2021 Sep 6.

Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay

William Mouton  1   2   3 , Christelle Compagnon  1   3 , Kahina Saker  1 , Soizic Daniel  4 , Sophia Djebali  2 , Xavier Lacoux  4 , Bruno Pozzetto  5   6 , Guy Oriol  1   3 , Daphné Laubreton  2 , Margaux Prieux  2 , Jean-Baptiste Fassier  7   8 , Nicolas Guibert  7   8 , Amélie Massardier-Pilonchéry  7   8 , Dulce Alfaiate  7   8 , Franck Berthier  4 , Thierry Walzer  2 , Jacqueline Marvel  2 , Karen Brengel-Pesce  1   3 , Sophie Trouiller-Assant  1   2
Affiliations

Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay

William Mouton et al. Eur J Immunol. 2021 Dec.

Abstract

Antigen-specific T-cells are essential for protective immunity against SARS-CoV-2. We set up a semi-automated whole-blood Interferon-gamma release assay (WB IGRA) to monitor the T-cell response after stimulation with SARS-CoV-2 peptide pools. We report that the WB IGRA is complementary to serological assays to assess SARS-CoV-2 immunity.

Keywords: SARS-CoV-2; T-cells response; immune memory; interferon gamma release assay.

PubMed Disclaimer

Conflict of interest statement

W.M., C.C., S.Da., X.L., G.O., F.B., and K.B.P. are employed in bioMérieux SA, an in vitro diagnostic company. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1
Figure 1
IFN‐γ release after in vitro WB stimulation using SARS‐CoV‐2 peptide pools. IFN‐ɣ levels measurement in WB of samples from SARS‐CoV‐2 convalescent HCWs (dot), three HCoV convalescent HCWs (square) and 25 controls (HV) (triangle). IFN‐ɣ secretion was measured on VIDAS automated platform (VIDAS® IFNɣ RUO, bioMérieux) after a 22‐h stimulation using (A) M peptides, (B) RBD peptides, and (C) N peptides. The median and individual secretion levels are shown. (D) Percentage of IFN‐ɣ positive CD4+ T‐cells measured by intracellular cytokine staining (ICS) following stimulation of PBMCs from a subset of patients (dot, n = 60) and new controls (HV) (triangle, n = 6) with a pool of peptides (PepTivator, Miltenyi Biotec) derived from Spike, N, and M proteins as detailed in the methods. Statistical differences were inferred using non‐parametric Kruskal‐Wallis test and Dunn's multiple comparisons test (A‐C) or Mann‐Whitney test (D) (***p < 0.001).
See this image and copyright information in PMC

References

    1. Sette, A. and Crotty, S. , Cell. 2021. 184: 861. - PMC - PubMed
    1. Skelly, D. T. et al., In Review. 2021: https://www.researchsquare.com/article/rs‐226857/v1
    1. Nelde, A. et al., Nat Immunol. 2021. 22: 74. - PubMed
    1. Le Bert, N. , et al., Nature. 2020. 584: 457. - PubMed
    1. Le Bert, N. et al., J. Exp. Med. 2021. 218: e20202617. - PubMed

Publication types

Substances